Zhan E, McIntosh VJ, Lasley RD. Adenosine A2A and A2B receptors are both required for adenosine A1 receptor-mediated cardioprotection. Am J Physiol Heart Circ Physiol 301: H1183-H1189, 2011. First published July 8, 2011; doi:10.1152/ajpheart.00264.2011.-All four adenosine receptor subtypes have been shown to play a role in cardioprotection, and there is evidence that all four subtypes may be expressed in cardiomyocytes. There is also increasing evidence that optimal adenosine cardioprotection requires the activation of more than one receptor subtype. The purpose of this study was to determine whether adenosine A2A and/or A2B receptors modulate adenosine A1 receptor-mediated cardioprotection. Isolated perfused hearts of wildtype (WT), A2A knockout (KO), and A2BKO mice, perfused at constant pressure and constant heart rate, underwent 30 min of global ischemia and 60 min of reperfusion. The adenosine A1 receptor agonist N 6 -cyclohexyladenosine (CHA; 200 nM) was administrated 10 min before ischemia and for the first 10 min of reperfusion. Treatment with CHA significantly improved postischemic left ventricular developed pressure (74 Ϯ 4% vs. 44 Ϯ 4% of preischemic left ventricular developed pressure at 60 min of reperfusion) and reduced infarct size (30 Ϯ 2% with CHA vs. 52 Ϯ 5% in control) in WT hearts, effects that were blocked by the A1 antagonist 8-cyclopentyl-1,3-dipropylxanthine (100 nM). Treatments with the A2A receptor agonist CGS-21680 (200 nM) and the A2B agonist BAY 60-6583 (200 nM) did not exert any beneficial effects. Deletion of adenosine A2A or A2B receptor subtypes did not alter ischemia-reperfusion injury, but CHA failed to exert a cardioprotective effect in hearts of mice from either KO group. These findings indicate that both adenosine A2A and A2B receptors are required for adenosine A1 receptor-mediated cardioprotection, implicating a role for interactions among receptor subtypes.
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A2a adenosine receptor; A2b adenosine receptor; knockout mice THE BENEFICIAL EFFECTS of adenosine in the ischemic-reperfused myocardium have been recognized for Ͼ25 yr. Adenosine can exert protection when given either before ischemia or at the onset of reperfusion. Substantial evidence now exists that these cardioprotective effects are achieved by the activation of extracellular adenosine receptors. All four adenosine receptor subtypes (A 1 , A 2A , A 2B , and A 3 ) are expressed in the heart, and there is evidence that all four receptors may be expressed in ventricular myocytes (4, 15, 26, 42) .
There is substantial evidence that the activation of all four adenosine receptors is cardioprotective, although there do appear to be differences in the specific roles of each receptor subtype. Activation of A 1 and A 3 receptors before ischemia is cardioprotective (2, 19, 20, 24, 30, 33, 37, 38, 41) , whereas A 2A and A 2B receptors appear to exert their effects during reperfusion (10, 13, 17, 18, 28, 34, 42, 43) . Adenosine A 3 receptor activation during reperfusion has been reported to be cardioprotective (8) , but there are conflicting reports on whether A 1 receptor activation during reperfusion is beneficial (3, 7, 30, 39, 40) . Likewise, all four adenosine receptors have been reported to activate protein kinases that appear to play a critical role in adenosine-mediated cardioprotection (9, 17, 33, 35) . The similar cardioprotective and signaling effects of all four adenosine receptors raise the question of whether there is redundancy in adenosine receptor cardioprotection or interactions among receptor subtypes (27, 32) .
There is increasing evidence that the expression and/or activation of more than one adenosine receptor subtype is needed for optimal protection from ischemia-reperfusion injury. We (19, 33) have previously reported that antagonism of adenosine A 2A and/or A 2B receptors with ZM-241385 blocked adenosine A 1 receptor agonist-mediated infarct size reduction in intact rats. Urmaliya et al. (39) reported that A 1 receptormediated protection of H9c2(2-1) cells during simulated ischemia was blocked by both A 2A and A 2B receptor antagonists. The authors concluded that endogenous adenosine activation of A 2A and A 2B receptors played a cooperative role in A 1 receptor protection. These same authors subsequently reported that reperfusion A 1 receptor-mediated infarct size reduction in mice also required the activation of A 2A and A 2B receptors, based on the use of receptor antagonists and adenosine A 2A receptor knockout (KO) mice (40) , although A 1 receptor-mediated preservation of left ventricular (LV) end-diastolic pressure (LVEDP) was maintained in A 2A KO hearts. There have been no reports to date providing direct evidence of A 2B receptors modulating A 1 receptor cardioprotection.
The purpose of this study was to determine whether the cardioprotective effects of adenosine A 1 receptor activation before ischemia and at the onset of reperfusion are modulated by A 2A and/or A 2B receptors. Experiments were conducted in isolated perfused hearts of wild-type (WT), A 2A KO, and A 2B KO mice.
MATERIALS AND METHODS
Animals. All animals in this study were maintained and used in accordance with guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and the Institutional Animal Care and Use Committee of Wayne State University. Experiments were conducted using male mice (10 -15 wk of age) on a C57BL/6 background. WT mice were purchased from Jackson Laboratories (Bar Harbor, ME). A2AKO and A2BKO male mice were bred from homozygous A2AKO and A2BKO breeders, which were generous gifts from Dr. Joel Linden (La Jolla Institute for Allergy and Immunology, La Jolla, CA) and Dr. Stephen Tilley (University of North Carolina, Chapel Hill, NC), respectively.
Genotypes were validated by PCR. The characterization of these two KO mouse models has been previously described in detail (5, 11) .
Isolated heart preparation. Hearts were excised from anesthetized (pentobarbital sodium, 60 mg/kg) and heparinized (500 units) mice, placed in ice-cold saline, and mounted on a perfusion apparatus in Յ90 s. The aorta was cannulated on a blunt 20-gauge needle, and perfusion was initiated at a constant pressure of 70 mmHg. Hearts were perfused with modified Krebs-Henseleit buffer (KHB), which contained (in mM) 116 NaCl, 11 glucose, 25 NaHCO 3, 4.7 KCl, 1.2 MgCl2, 1.2 KH2PO4, 2.0 CaCl2, 0.05 EDTA, and 2 pyruvate. The fluid was bubbled with a mix of 95% O2 and 5% CO2 at 37°C to maintain a pH of 7.4 and was filtered through an in-line 0.45-m filter.
A fluid-filled balloon was introduced into the LV through an incision in the atrial appendage to record ventricular function. The balloon was inflated to yield a LVEDP of 5-8 mmHg during the stabilization period. Temperature was maintained at 37°C with constant-temperature reservoirs and by partially submerging the heart into a water-jacketed chamber filled with KHB. Ventricular function (LV pressure, ϩdP/dt, and ϪdP/dt), heart rate, coronary flow (CF), and coronary perfusion pressure were continuously monitored and recorded throughout the experiments. All data were collected and analyzed using PowerLab data-acquisition systems and LabChart Software for Windows (AD Instruments, Colorado Springs, CO). Hearts were paced at 420 beats/min via pacing wires inserted into the right ventricle.
Experimental protocols. All hearts underwent 30 min of global ischemia followed by 60 min of reperfusion.
Hearts were allowed 15-20 min of stabilization after instrumentation before the experimental protocols were initiated. Mice were divided into six primary groups:
Five additional groups (n ϭ 4 -5 mice/group) of WT mice were studied to confirm the A1 receptor cardioprotective effect of CHA and to determine the effects of A2A and A2B receptor activation and blockade. These groups were as follows: 1) WT ϩ the adenosine A1 
The three adenosine receptor agonists were administered for 10 min before ischemia and for the first 10 min of reperfusion. Treatment with the A 1 receptor antagonist DPCPX was initiated 5 min before CHA and then administered concurrently with the agonist. In the final two groups, SCH-58261 and MRS-1754 were administered for the first 10 min of reperfusion in the presence of CHA to determine whether A 1 agonist protection requires A2A or A2B receptor activation during this period. The selectivity of these various agonists and antagonists for their respective receptors has been previously established (1, 12, 16, 21, 29, 44) .
Drugs. CHA, DPCPX, and CGS-21680 were obtained from SigmaAldrich (St. Louis, MO). SCH-58261 and MRS-1754 were obtained from Tocris-Cookson (Ellisville, MO). The A 2B receptor agonist BAY 60-6583 was a kind gift from Dr. Thomas Krahn (Bayer Healthcare, Wuppertal, Germany). All of these agents were made as concentrated stock solutions (10 mM) in DMSO and then diluted in distilled H 2O to 2 mM. The diluted solutions were added directly to the KHB immediately before use.
Determination of myocardial necrosis. At the end of the reperfusion period, hearts were removed from the cannula, the aorta and atria were removed, and hearts were weighed. Hearts were sliced into five pieces parallel to the long axis and immersed in 1% triphenyltetrazolium chloride buffer (37°C) for 15 min and then in 10% neutralbuffered formalin for 10 min to enhance the contrast between triphenyltetrazolium chloride-negative and -positive staining. After removal of the right ventricle, heart sections were then photographed with a digital camera, and infarct size was quantified using SigmaScan Pro 4.0 software (Jandel Scientific, San Rafael, CA). Infarct size was expressed as a percentage of the total LV.
Statistical analysis. Data are expressed as means Ϯ SE. Baseline hemodynamic parameters among the groups were analyzed by oneway ANOVA. Differences between baseline and CHA treatments were analyzed by two-way ANOVA with repeated measures. Differences in postischemic function and infarct size among the experimental groups were analyzed by two-way ANOVA followed by a Bonferroni post hoc test. Differences were considered statistically significant at P Ͻ 0.05.
RESULTS
Baseline hemodynamics and the effects of the A 1 agonist CHA before ischemia are shown in Table 1 . There were no significant differences in any baseline parameter in WT, A 2A KO, and A 2B KO hearts. CHA significantly increased all four hemodynamic parameters [LV developed pressure (LVDP), ϩdP/dt, ϪdP/dt, and CF] in WT and A 2B KO mice (P Ͻ 0.05). In A 2A KO mice, A 1 receptor agonist treatment increased ϪdP/dt (P Ͻ 0.05) but had no effect on LVDP, ϩdP/dt, or CF. The postischemic recovery of LVDP is shown in Fig. 1 Figure 2 shows the effects of A 1 agonist treatment on the recovery of ϩdP/dt. In WT hearts, CHA increased the postischemic recovery of ϩdP/dt at both 30 min (74 Ϯ 4% vs. 47 Ϯ 5%, P Ͻ 0.05) and 60 min (85 Ϯ 5% vs. 52 Ϯ 5%) of reperfusion. Deletion of adenosine A 2A and A 2B receptors did not alter the recovery of ϩdP/dt compared with WT hearts, but it prevented A 1 agonist improvement in this contractile parameter. Similarly, the improvement in postischemic ϪdP/dt recovery with A 1 agonist treatment was prevented in A 2A KO and A 2B KO hearts (data not shown).
Reperfusion LVEDP results are shown in Fig. 3 . There were no differences in end-ischemic diastolic pressures among the groups. CHA significantly decreased LVEDP in WT hearts throughout reperfusion; after 60 min of reperfusion, LVEDP values were reduced from 36 Ϯ 2 mmHg in control hearts to 20 Ϯ 2 mmHg in CHA-treated hearts. Deletion of A 2A and A 2B receptors alone exerted no effects on postischemic LVEDP, but, as with the aforementioned contractile parameters, these hearts exhibited no improvement in reperfusion LVEDP.
Myocardial infarct size results are shown in Fig. 4 . The A 1 agonist CHA significantly decreased infarct size in WT mice from 52 Ϯ 5% to 30 Ϯ 2%. Infarct sizes in control A 2A KO (46 Ϯ 4%) and A 2B KO (52 Ϯ 5%) hearts were similar to control WT hearts. Treatment with CHA exerted no beneficial effect on infarct size in either KO heart.
Additional experiments in WT hearts were conducted to verify that the effects of CHA were mediated via A 1 receptor activation and to determine whether A 2A and A 2B receptor activation and blockade modulated ischemia-reperfusion injury. As shown in Fig. 5 , hearts treated with the A 1 receptor antagonist DPCPX ϩ CHA exhibited 27 Ϯ 6% recovery of LVDP after 60 min of reperfusion and an infarct size of 58 Ϯ 5% (P Ͻ 0.05 vs. CHA). Hearts treated with the A 2A agonist CGS-21680 and the A 2B agonist BAY 60-6583 using the same concentration and treatment protocol as used with CHA did not show evidence of cardioprotection. These hearts recovered only 24 Ϯ 6% and 42 Ϯ 4% of preischemic LVDP and had infarct sizes of 65 Ϯ 1% and 57 Ϯ 6%, respectively. Although brief activation of A 2A and A 2B receptors was not protective, the results of additional experiments indicated that A 2A (SCH-58261) and A 2B (MR-S1754) receptor antagonists administered only during the reperfusion phase of CHA treatment significantly reduced the beneficial effects of this A 1 agonist. The recovery of LVDP in hearts treated with SCH-58261 and MRS-1754 was comparable to that seen in control WT hearts and was statistically different (P Ͻ 0.05) than that observed in CHA-treated hearts. Similar findings in all of these groups on reperfusion LVEDP and ϩdP/dt were also observed (data not shown). Antagonism of A 1 receptors with DPCPX throughout the CHA treatment protocol blocked the A 1 infarct-reducing effect, and neither CGS-21680 nor BAY 60-6583 mimicked the beneficial effects of CHA. Hearts coinfused with SCH-58261 and MRS-1754 during reperfusion CHA treatment exhibited infarct sizes similar to control hearts, although these values were not statistically different from CHA infarct sizes.
DISCUSSION
The results of this study indicate that adenosine A 1 receptorinduced cardioprotection in isolated perfused mouse hearts requires the expression and/or activation of additional adenosine receptor subtypes. Although neither deletion of A 2A or A 2B receptors nor brief activation of these receptors altered ischemia-reperfusion injury, KO of either receptor blocked the beneficial effects of adenosine A 1 receptor stimulation on postischemic function and infarct size. The results of additional experiments in WT hearts indicated that pharmacological blockade of A 2A or A 2B receptors only during the reperfusion phase of CHA treatment completely blocked A 1 agonist-induced functional protection and reduced the extent of A 1 receptor-mediated infarct reduction. These observations indicate that maximal adenosine A 1 receptor cardioprotection requires the input of more than one receptor subtype and support the hypothesis of interactions among adenosine receptor subtypes.
All four adenosine receptor subtypes are expressed in mammalian myocardium, and there is evidence that all four subtypes may be expressed in cardiac myocytes. In addition, all four adenosine receptors have been reported to reduce myocardial ischemia-reperfusion injury in multiple species (10, 27, 32) . This raises the question of whether adenosine cardioprotection is modulated by interactions among adenosine receptor subtypes. Interactions among adenosine receptor subtypes have been reported in transfected cells and in the brain (14, 22, 23) , and there is increasing evidence for adenosine receptor interactions in the heart (4, 19, 31, 40, 42) . This is the first study to document that adenosine A 1 receptor cardioprotection requires the activation of both A 2A and A 2B receptor subtypes.
Previous studies (19, 33, 39, 40) have provided evidence that adenosine A 2 receptor subtypes modulate adenosine A 1 receptor cardioprotection. We (19, 33) have reported that the adenosine receptor antagonist ZM-241385, which can block both A 2A and A 2B receptors, inhibited in vivo A 1 receptor cardioprotection in rats. Urmaliya et al. (40) recently reported that the same antagonist blocked reperfusion A 1 agonist cardioprotection in the isolated mouse heart. However, ZM-241385, which was developed as a potent and selective adenosine A 2A receptor antagonist, has been shown to also have affinities of Յ100 nM for adenosine A 2B receptors in multiple species, including the mouse (1). This indicates that alterations in adenosine receptor effects by ZM-241835 may be due to either A 2A or A 2B receptors.
The results of the present study indicate that neither deletion of A 2A receptors nor administration of an A 2A receptor agonist altered myocardial ischemia-reperfusion injury. However, A 2A receptor deletion did block A 1 receptor-induced cardioprotection. Our observations are consistent with the recent findings of Urmaliya et al. (40) , who also reported that deletion of the A 2A receptor blocked A 1 cardioprotection in the isolated mouse heart. However, we administered CHA for 10 min before ischemia and 10 min at the onset of reperfusion, resulting in modulation of both ischemia and reperfusion injury, whereas in the previous report (40) A 1 receptor stimulation was limited to only the first 15 min of reperfusion, thus modulating only reperfusion injury. We did not limit A 1 agonist treatment to just the reperfusion period since there are reports (3, 37) showing that reperfusion A 1 receptor stimulation does not exert beneficial effects. In contrast to Urmaliya et al. (40), we observed no preservation of reperfusion LVEDP in A 2A KO hearts treated with CHA, and infarct sizes in our control hearts were ϳ50%, in contrast to control infarcts in their study of only ϳ30%. These differences could be due to the differences in the strains of mice, as we used C57Bl/6 mice and Urmaliya et al. (40) used CD-1 mice.
Much less is known about the role of A 2B receptors in myocardial ischemia-reperfusion injury, although there are reports (17, 28, 42) showing that A 2B receptor stimulation during reperfusion is cardioprotective. As stated above, our previous reports (19, 33) demonstrating that ZM-241385 blocked A 1 cardioprotection could have been the result of antagonism of A 2B receptors due to the high affinity of this antagonist for A 2B receptors (1). Urmaliya et al. (40) recently reported that the beneficial effects of reperfusion treatment with an A 1 agonist in isolated perfused mouse hearts was blocked by the A 2B antagonist MRS-1754. Our present observations support these observations, as all of the beneficial effects of CHA were blocked in A 2B KO hearts, although deletion of A 2B receptors had no effect alone on ischemiareperfusion injury, nor did brief treatment with the A 2B agonist BAY 60-6583. Previous studies in A 2B KO mice have yielded conflicting results, as Eckle et al. (6) reported that ischemic preconditioning in in vivo murine myocardium was blocked in A 2B KO mice, but Maas et al. (25) observed no loss of ischemic preconditioning protection in A 2B KO isolated mouse hearts. The present study is the first to report that A 2B receptors are necessary for A 1 cardioprotection.
Our observations that brief treatments with CGS-21680 and BAY 60-6583 exerted no beneficial effects indicate that CHA was not merely nonselectively activating A 2A or A 2B receptors. These findings may initially appear to contradict the numerous reports (10, 13, 17, 18, 28, 30, 34, 42, 43) showing that reperfusion infusions of A 2A and A 2B receptor agonists are cardioprotective. However, beneficial effects of A 2A and A 2B receptor agonists have been observed after prolonged (Ն60 min) agonist infusions. In addition, the beneficial effects of reperfusion A 2A agonists have been demonstrated primarily in in vivo preparations (13, 18, 28, 30, 43) , with few such observations in isolated perfused hearts (34) . There are two previous reports (6, 25) showing that treatment with the A 2B receptor agonist BAY 60-6583 before ischemia reduces myocardial infarct size in intact mice and rats. However, in these studies, BAY 60-6583 was administered Ն30 min before myocardial ischemia. In the present study, reperfusion treatments with CGS-21680 and BAY 60-6583 were limited to only the first 10 min of reperfusion (in addition to the 10-min preischemic treatment) to directly compare the effects of A 2A and A 2B receptor activation with the same dose and timing that we used with the A 1 agonist CHA.
Another interesting aspect of the present findings is that although A 1 agonist treatment included both preischemic and early reperfusion components, including the A 2A (SCH-58261) or A 2B (MRS-1754) receptor antagonists only during the reperfusion phase significantly blunted A 1 receptor agonist cardioprotection in WT hearts. Functional protection with CHA was completely lost with these two antagonists, whereas infarct size was similar to control WT hearts but not statistically different from that observed with CHA. These observations indicate that A 2A and A 2B receptor stimulation during reperfusion play a key role in A 1 agonist-induced cardioprotection. We were surprised by this observation since we included 10 min of preischemic CHA treatment and hearts were exposed to this agonist throughout the 30-min ischemic period. Urmaliya et al. (40) arrived at similar conclusions when A 1 agonist treatment was limited to only the first 15 min of reperfusion.
Our present findings using both genetic and pharmacological blockade of A 2A and A 2B receptors indicate that these two receptors are both necessary for optimal A 1 receptor-mediated cardioprotection. These observations suggest that there may be functional and/or physical interactions among these receptor subtypes. Stimulation of A 1 , A 2A , and A 2B receptors in several tissues, including the heart, all activate similar protein kinase signaling pathways, which have been implicated in adenosine receptor cardioprotection (17, 27, 32, 33, 35) . These results suggest that receptor cross-talk may be necessary to provide optimal subcellular signaling to induce adenosine A 1 receptormediated cardioprotection.
There is increasing evidence for interactions among adenosine receptors in several tissues, including the heart. Lopes et al. (23) first reported evidence of A 1 and A 2A receptor functional interactions in rat hippocampal and cortical synaptosomes based on the observations that A 2A receptor stimulation suppressed A 1 receptor agonist binding. It has been reported that adenosine A 2B receptor expression is increased in A 2A KO mice (4, 5, 36) . Norton et al. (31) concluded that the A 2A receptor blunted the A 1 receptor antiadrenergic effect in rat hearts, and we (4) have recently observed potentiation of the A 1 antiadrenergic effect in A 2A KO, but not A 2B KO, mice. In that same study (4), BAY 60-6583, but not CGS-21680, produced dose-dependent increases in contractility. In the present study, we observed that preischemic infusion of CHA exerted a small, but statistically significant, increase in contractility in WT and A 2B KO hearts but not in A 2A KO hearts. The above observations suggest that A 2A and A 2B receptors differentially modulate A 1 receptor effects on contractility but tht both receptors play an important role in A 1 cardioprotection.
In summary, our present findings support the hypothesis of cross-talk between adenosine A 1 and A 2 receptor subtypes in the mouse myocardium. Both A 2A and A 2B receptors are necessary for A 1 receptor-mediated myocardial protection, and these effects appear to manifest themselves primarily during reperfusion.
